Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 11

  • 1 206 clinical trials
  • 460 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia80Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Plasma cell myeloma refractory42Follicular lymphoma41Mantle cell lymphoma33Myelofibrosis32B-cell small lymphocytic lymphoma29Chronic myeloid leukaemia29Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17Paroxysmal nocturnal haemoglobinuria17B-cell lymphoma refractory16B-cell type acute leukaemia16Anaemia14+340

Clinical trials in Blood and lymphatic system disorders

1 206 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 206 clinical trials

Myelodysplastic syndrome

Recruiting

Study of momelotinib tablets in patients with anemia caused by low-risk myelodysplastic syndrome

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Plasma cell myeloma

Recruiting

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Myelodysplastic syndrome+1

Recruiting

Study of momelotinib in patients with VEXAS syndrome and myelodysplastic syndrome who are dependent on or do not respond to steroid treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Groupe Francophone Des Myelodysplasies

Acute lymphocytic leukaemia+1

Recruiting

Study of TdT-3 cell therapy safety in patients aged 1 year and older with relapsed or refractory acute leukemia or lymphoblastic lymphoma

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:TDT-3
  • Sponsor:Oslo University Hospital HF

Acute myeloid leukaemia+1

Recruiting

Study of venetoclax, treosulfan and fludarabine before stem cell transplant in patients with acute myeloid leukemia and myelodysplastic syndrome

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Treosulfan
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Primary mediastinal large B-cell lymphoma+3

Recruiting

Study of dapagliflozin to prevent heart complications during lymphoma treatment in patients receiving first-line therapy

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Aalborg University Hospital

Chronic lymphocytic leukaemia+5

Recruiting

Study of NX-5948 in adults with relapsed or resistant chronic lymphocytic leukemia and small lymphocytic lymphoma who previously received BTK inhibitor and BCL-2 inhibitor treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:NX-5948
  • Sponsor:Nurix Therapeutics Inc.

Immune thrombocytopenia

Recruiting

Study of efgartigimod given by IV infusion in adolescents aged 12-17 years with chronic immune thrombocytopenia

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Acute myeloid leukaemia

Recruiting

Study of gilteritinib with fludarabine, cytarabine and idarubicin combination therapy in newly diagnosed FLT3-positive acute myeloid leukemia patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Gilteritinib
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Glomerulonephritis membranous+4

Recruiting

Study of Atacicept Treatment for Patients with Multiple Autoimmune Glomerular Diseases

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Atacicept
  • Sponsor:Vera Therapeutics Inc.

Autoimmune haemolytic anaemia

Recruiting

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Plasma cell myeloma

Recruiting

Study of ABBV-453 alone or with drug combination for adults with multiple myeloma: evaluation of safety and effectiveness

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab121 clinical trialsVenetoclax115 clinical trialsCyclophosphamide99 clinical trialsLenalidomide99 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.